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groups. Higher NT-proANP levels were found in group II compared to group IV (0.1425
vs. 0.078 nmol/L, p=0.04) and higher BNP levels in group II compared to group III
(897.37 vs. 419.4 pg/ml, p=0.016). One day before profound cardiogenic shock occurred
NT-pro ANP, BNP and big ET-1 were elevated in group II compared to group III (0.126 vs.
0.094 nmol/L, p=0.049; 848.23 vs. 342.2 pg/ml, p=0.016; 20.7 vs. 5.65 pg/ml, p=0.019
resp.). NT-proBNP remained unchanged during treatment in groups II and III but
decreased significantly in group IV (p = 0.9, p = 0.6 and p = 0.025 resp.). 
Conclusion: While routine parameters did not predict the clinical course, natriuretic pep-
tides showed significant differences between groups on admission and before clinical
deterioration.
Daily measurement of natriuretic peptides may be used to determine optimal time-point
for HTx or VAD implantation in patients with severe end-stage heart failure.
1049-108 B-Type Natriuretic Peptide and Chest Radiograph 
Findings as Indicators of Systolic Dysfunction in 
Patients Presenting With Acute Dyspnea
Cathrine Wold Knudsen, Torbjorn Omland, Arne Westheim, Paul Clopton, William T. 
Abraham, Alan Storrow, James K. McCord, Richard Nowak, Philippe Duc, Peter 
McCullough, Alan Maisel, Ullevaal University Hospital, Oslo, Norway, VA San Diego 
Healthcare System, San Diego, CA
Background: The diagnosis of left ventricular (LV) systolic dysfunction may be difficult in
acute dyspneic patients. Chest radiographs are routinely performed, but are not always
diagnostically definitive. Objective: To compare the diagnostic value of chest radiograph
findings with that of B-type natriuretic peptide (BNP) testing as indicators of LV ejection
fraction < 35%. Methods: The Breathing Not Properly Study was a multinational study
evaluating the diagnostic accuracy of BNP in 1586 patients presenting with acute dysp-
nea. Chest radiographs and echocardiograms permitting estimation of LV ejection frac-
tion were available in 709 of the patients. BNP was measured on arrival in all patients.
Two cardiologists blinded to BNP results reviewed all clinical data and categorized
patients as to whether they had acute heart failure (63.8%) or not (36.2%). Results: Diag-
nostic information from chest radiographs and from BNP is presented in the Table. Multi-
variate logistic regression showed that both BNP > 100 pg/ml (OR: 8.1 (95% CI: 3.8-
17.6)) and chest radiograph findings of cardiomegaly (OR: 2.3 (95% CI: 1.4-3.8)) and
pleural effusion (OR: 1.8 (95% CI: 1.2-2.9)) added significant, predictive information
above historical and clinical predictors of systolic dysfunction. Conclusion: In patients
presenting with acute dyspnea, BNP and chest radiographs provide complementary
diagnostic information. Both methods should both be utilized in the early evaluation of LV
systolic dysfunction.
1049-109 Evaluation of B-Type Natriuretic Peptide Levels in 
Normal and Pre-Eclamptic Women During Pregnancy
Jennifer Beede, Vikas Bhalla, Radmila Kazanegra, Alan S. Maisel, Veteran's Affairs 
Medical Center, San Diego, CA, University of California, San Diego, CA
OBJECTIVE: B-type natriuretic peptide (BNP) is synthesized in cardiac ventricular tissue
in response to volume expansion and pressure overload. It is an approved marker for the
diagnosis of congestive heart failure (CHF) in patients with dyspnea in an acute care set-
ting. BNP levels correlate to wedge pressure, severity of CHF, and medical prognosis.
BNP has also been used to screen for ventricular dysfunction in high-risk patients such
as diabetics and hypertensives. The objective of this study was to determine whether
BNP levels fluctuated during pregnancy, and if BNP could be a useful diagnostic tool in
preeclamptic women.
DESIGN: We studied 195 BNP levels in 78 women longitudinally from the first trimester
to term. An additional 33 patients admitted with preeclampsia (9 mild, 24 severe) were
studied and compared to 21 normal controls with term pregnancies. Plasma BNP values
were determined using a standard point of care assay.
RESULTS: BNP levels did not change significantly across gestation in normal pregnant
women. In early pregnancy, BNP values are 25 pg/ml ± 2.4, and at term, values are 22
pg/ml ± 3.6. BNP remains stable at this level throughout the midtrimester. Patients with
mild preeclampsia had higher BNP levels than controls, however this difference was not
statistically significant (44.4 v. 22.1 pg/ml, p >.05). Women with severe preeclampsia, in
the absence of evidence of clinical cardiac disease, had mean BNP levels of 124.6 v.
22.1pg/ml in controls (p=0.017).
CONCLUSION: In normal pregnancies, BNP values are stable throughout gestation.
Patients with severe preeclampsia have elevated BNP values. This may reflect ventricular
stress and/or subclinical cardiac dysfunction associated with the disease process.
1049-110 Circulating Beta-Atrial Natriuretic Peptide in Human 
Coronary Artery Disease: A New Marker for Stage A 
Heart Failure?
Fernando L. Martin, Alessandro Cataliotti, Shang-Chiun Lee, John A. Schirger, Denise 
M. Heublein, Lisa C. Costello-Boerrigter, Guido Boerrigter, John C. Burnett, Jr., Mayo 
Clinic and Foundation, Rochester, MN
Background: Studies have reported the presence of an antiparallel dimer form of atrial
natriuretic peptide (ANP) named β-ANP in both atrial tissue and plasma of normal
humans. β-ANP has been shown to be elevated in patients with severe congestive heart
failure (CHF). Its biological significance is that it may have reduced cGMP enhancing
actions compared to native ANP and its formation may be secondary to states of oxida-
tive stress within the myocardium and plasma. To date, it is unknown whether β-ANP is
elevated in patients with CAD independently of co-presence of left ventricular dysfunction
(LVD) which represents Stage A of CHF. The aim of this study was to determine the con-
centration of β-ANP in patients with CAD. We hypothesized that plasma concentration of
β-ANP is elevated in patients with CAD independently of concomitant LVD.
Methods: We prospectively enrolled 58 subjects (33 men), average age 66 (41 to 84),
with CAD referred to the Mayo Clinic Cardiac Catheterization Laboratory. Ejection frac-
tion (EF) was assessed by echocardiogram. Subjects were divided in two subgroups
according to EF (EF> or EF< 50%). Twenty normal subjects served as a control group. β-
ANP was measured by RIA. * indicates p<0.05 versus CAD.
Results: β-ANP was elevated in CAD patients compared to normal subjects (25.4±4.2
CAD versus 7±0.7 normal*). When analyzed by subgroups, β-ANP tended to increase in
the subgroup (n=13) with EF<50% compared with subjects with EF > 50% (n=45)
(p=0.05). Importantly, β-ANP was significantly elevated in the subgroup with EF > 50% as
compared to normal (22.4±4.4 CAD > 50% EF versus 7±0.7 normal*). An inverse corre-
lation was observed between β-ANP and EF (Spearman r= -0.3219; 95% C.I. -0.539 to -
0.064; p=0.0065).
Conclusion: We report for the first time that β-ANP is elevated in patients with CAD and
is inversely correlated with EF. More importantly, β-ANP is elevated in subjects with CAD
and normal EF (Stage A CHF). β-ANP may be a useful marker to identify patients with
CAD independently of co-existing LVD who are at risk for progression to CHF increasing
our available biomarkers for cardiovascular disease.
1049-111 Plasma B-Type Natriuretic Peptide in Obstructive Sleep 
Apnea
Anna Svatikova, Abu S. Shamsuzzaman, Robert Wolk, Bradley G. Phillips, Lyle J. Olson, 
Virend K. Somers, Mayo Clinic, Rochester, MN
Background: Obstructive sleep apnea (OSA) has been associated with several cardio-
vascular diseases. Brain natriuretic peptide (BNP), released by the ventricles in response
to high wall tension, has been linked to development of hypertension, heart failure and
nocturnal angina. OSA is also associated with these disease conditions and activates
those mechanisms implicated in BNP release. The aim of the present study was to clarify
whether plasma BNP is acutely or chronically increased by OSA, either in otherwise
healthy subjects, or in subjects diagnosed with both OSA and chronic heart failure (CHF),
or OSA and other cardiovascular diseases.
Methods: Plasma BNP levels were measured in 23 patients with moderate to severe
OSA who were either otherwise healthy (n=10) or who also had concomitant cardiovas-
cular disease (n=13, 5 patients with both OSA and CHF, 8 patients with OSA and non-
CHF cardiovascular disease). BNP was obtained on three occasions: first before sleep,
then after 5 hours of untreated OSA, and again in the morning, after 4 hours of effective
treatment with continuous positive airway pressure (CPAP). BNP levels were also mea-
sured in 10 closely matched, normal healthy subjects at similar time points.
Results: Baseline BNP levels were similar in the 10 otherwise healthy OSA subjects and
the 10 normal controls before sleep (6.1±10.2 vs. 6.2±10.2 pg/mL respectively, P=0.96)
and were unaffected by several hours of untreated OSA and by acute CPAP treatment.
BNP levels at baseline were higher, compared to controls, in 5 OSA patients with CHF
(90.2±14.4 pg/mL, P=0.0016) and in 8 OSA patients with other non-CHF cardiovascular
diseases (31.7±11.4 pg/mL, P=0.05). These high levels of BNP remained stable through
the night in the OSA with CHF and the OSA with non-CHF cardiovascular disease
groups, completely unaffected either by several hours of acute untreated OSA or by
CPAP treatment.
Conclusions: Despite the metabolic and mechanical stresses elicited by OSA, OSA in
and of itself does not increase plasma BNP in otherwise healthy subjects during wakeful-
ness. OSA does not elicit acute sleep-related changes in BNP in healthy OSA subjects
nor in patients with coexisting cardiovascular disease, including CHF.
1049-112 Utility of B-Type Natriuretic Peptide and ProBNP in 
Evaluation of Patients Receiving Natrecor Therapy 
(UBET Study)
Robert L. Fitzgerald, Rosemary Cremo, Nancy Gardetto, Albert Chiu, Vikas Bhalla, Alan 
S. Maisel, VA San Diego Healthcare System, San Diego, CA, University of California, 
San Diego, CA
BACKGROUND: B type natriuretic peptide (BNP) is synthesized in cardiac ventricles as
a prohormone (108 amino acids) and during the release process is cleaved into the
active hormone BNP (AA 77-108) and an inactive fragment proBNP (AA 1-76). We deter-
mined the effect of Natrecor (human recombinant BNP) infusions on the concentrations
of BNP and proBNP.
METHODS: Three groups of acutely decompensated congestive heart failure (CHF)
patients received Natrecor (2 ug/kg iv bolus followed by a 0.01 ug/kg/min infusion) for 24,
36 or 48 hours (N = 10, 9 and 8 respectively). Serial blood samples were collected during
and after the infusion, BNP (Biosite and Bayer Diagnostics) and proBNP (proBrain Natri-
uretic Peptide, Roche Diagnostics) were measured.
Diagnostic performance of chest radiograph variables and BNP
Variable Sensitivity (%) Specificity (%) Accuracy (%)
Cardiomegaly 85 50 61
Cephalisation 34 80 66
Pleural effusion 31 84 67
BNP > 100 pg/mL 94 41 57
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RESULTS: The two methods of measuring BNP (Biosite and Bayer) gave nearly identical
results. One hour following a bolus dose of Natrecor, the average concentrations of BNP
increased about three fold (<0.001). For example, in patients who received the 48 hour
infusion, the average baseline, 1 hour, 48 hour and 12 hour post infusion concentrations
of BNP (Biosite assay) were 1100, 3700, 1900 and 600 pg/mL respectively. The 12 hour
post infusion concentration of BNP was significantly lower (<0.05) than baseline for this
group. In contrast to the BNP results, proBNP concentrations did not increase following
Natrecor administration. For example, in the 48 hour infusion group, the average base-
line, 1 hour, 48 hour and 12 hour post infusion concentrations of proBNP were 9600,
9100, 4400 and 4400 pg/mL respectively. At the end of the infusion and 12 hours after
the infusion, the concentrations of proBNP were significantly (<0.001) lower than base-
line for this group. The proBNP results were not as easily interpreted for the groups that
received infusions < 48 hours.
CONCLUSION: Following the bolus dose, average BNP concentrations trended down
during the infusion, suggesting both drug clearance and turn-off of endogenous synthe-
sis. The decrease in proBNP likely reflects turn-off of endogenous synthesis. Thus both
BNP (endogenous and drug) and proBNP (endogenous secretion) levels can be used to
monitor the concentrations of these peptides in patients administered Natrecor.
1049-113 Prospective Study in Search of an Optimal B-Type 
Natriuretic Peptide Level to Screen Patients for Cardiac 
Dysfunction
Meenakshi A. Bhalla, Vikas Bhalla, Dunya Atisha, L. Katherine Morrison, Leda Felicio, 
Paul Clopton, Nancy Gardetto, Radmila Kazanegra, Albert Chiu, Alan S. Maisel, 
Veteran's Affairs Medical Center, San Deigo, CA, University of California, San Diego, CA
BACKGROUND: Although echocardiography is the gold standard test for the suspected
Left Ventricular dysfunction (LVD),the cost and availability, limits its use as a routine
screening tool. Determining an appropriate BNP level below that would preclude the
need for echocardiography would be valuable. We hypothesized that a fixed plasma BNP
level of 20pg/ml and simple clinical parameters would be an effective pre-echocardio-
graphic screening tool for LV dysfunction. METHODS: 202 VA subjects with symptoms
suggestive of heart disease (m:f 193:9, mean-age 65) were screened prior to echocar-
diography. Patients with known cardiac dysfunction were excluded. RESULTS: BNP lev-
els of 20pg/ml and above were 79% sensitive and 44% specific in screening for any
abnormality of ventricular function.The negative predictive value was 69%.When broken
down into categories of dysfunction, the cut point of 20pg/ml had a better negative pre-
dictive value for those with systolic dysfunction (96%), or systolic plus diastolic dysfunc-
tion (100%) if patients with diastolic dysfunction were excluded. The majority of patients
with falsely low BNP levels (<20pg/ml with positive echo findings) had mild diastolic dys-
function,with 3 patients exhibiting mild systolic dysfunction. CONCLUSION: BNP may be
useful screening tool for LVD in patients with history suggestive of heart disease and may
assist in forming a pre-test probability which could greatly assist in appropriateness of
patient referral and in optimization of drug therapy.
1049-114 Increasing Atrial Natriuretic Peptide Over Time 
Independently Predicts Higher Short-Term Mortality and 
Morbidity in Heart Failure
Raymond T. Yan, Rizwan Afzal, Robert S. McKelvie, McMaster University, Hamilton, ON, 
Canada
Background: Baseline measurements of various neurohormones (NH) have been
reported as useful prognostic markers in heart failure (HF). However, the prognostic val-
ues of changes in these different NH over time have not been examined.
Methods: We evaluated 768 subjects with symptomatic HF and left ventricular ejection
fraction <0.40 randomized to various combinations of candesartan, enalapril and meto-
prolol in RESOLVD. Changes (∆) (week 17 - baseline) in each measured NH were com-
pared between subjects with and without subsequent (week 17 to week 43) death or HF
hospitalization, and their independent prognostic significance were determined by Cox
regression analysis.
Results: All NH were abnormally elevated at baseline. Subjects who subsequently died
or required hospitalization for HF had significantly larger increases in atrial natriuretic
peptide (ANP) and smaller decreases in norepinephrine (NE). In Cox regression analy-
sis, every 2-fold increase in ANP over time independently predicted an increased risk of
subsequent death or HF hospitalization (Hazard ratio 1.53, 95% CI 0.93 to 3.63, p=0.07).
Changes in other NH conferred no incremental prognostic value. 
Conclusion: Increasing ANP over time independently predicted a trend towards higher 
short-term mortality and morbidity in chronic HF patients on neurohormonal therapies. 
Serial measurements for changes in ANP may help to identify higher risk HF patients and 
should be evaluated in further studies.
1049-115 The Value of B-Type Natriuretic Peptide and Cardiac 
Troponin I as Predictors of Sudden Death in Patients 
With Advanced Heart Failure
Mark M. Lensky, Tamara B. Horwich, Gregg C. Fonarow, University of California at Los 
Angeles Medical Center, Los Angeles, CA
Objectives: The study aimed to evaluate the potential role of BNP and cardiac troponin I
(TnI) as predictors of sudden death (SD) in patients with advanced heart failure (HF).
Background: Earlier studies have reported that BNP and TnI are predictive of mortality
in HF patients: their role in predicting SD in HF has not been well studied.
Methods: We analyzed 757 advanced HF patients followed in a comprehensive HF man-
agement program of which 303 had baseline BNP and 403 had TnI determined. The
patients were grouped into those with undetectable TnI < 0.04 ng/mL (n = 187) and
detectable TnI > 0.04 (n = 216) as well as those with BNP < 950 pg/mL (n= 226) and
BNP > 950 (n =77). The BNP cut point was selected based on ROC curves for SD.
Results: Of 110 deaths during 2 years of follow-up 42 (38%) were classified as SD.
Detectable TnI (OR 2.81, 95% CI 1.70-4.64) and BNP > 950 (OR 8.76, 95% CI 4.65-
19.50) predicated significantly increased risk of all-cause mortality. While BNP > 950 was
highly predictive of SD risk (OR 4.75, 95% CI 1.32-17.15), detectable TnI was only asso-
ciated with a non-significant trend (OR 1.72, 95% CI 0.78-3.79). On multivariate analysis,
BNP < 950 was a strong predictor of SD free survival; non-detectable TnI was not.
Conclusions: In a large cohort of patients with advanced HF of multiple etiologies, ele-
vated BNP, but not detectable TnI, is highly predictive of increased risk for SD. Prospec-
tive studies are needed to test if BNP can be used to guide prophylactic Implantable
Cardioverter Defibrillator device placement in HF.
1049-116 B-Type Natriuretic Peptide Does Not Correlate With 
Volume Overload or Left Ventricular Dysfunction in 
Patients With Multiple Comorbidities
Sukesh C. Burjonroppa, Mary Vooletich, Daniel J. Lenihan, University of Texas, MD 
Anderson Caner Center, Houston, TX
Background: B type Natriuretic peptide (BNP) has been shown to be an important
marker of left ventricular (LV) systolic dysfunction and volume overload (VOL) in patients
with symptomatic heart failure (HF).In addition, the level of BNP elevation in HF has cor-
related with prognosis. However marked elevation of BNP can be noted without VOL.
Thus, we hypothesized that these elevated BNP levels may reflect non-specific eleva-
tions due to co-morbid diseases rather than due to VOL alone.
Methods: Over a 6-month period, all patients admitted with BNP levels greater than
1000 pg/ml were identified. The demographics, co-morbidities including the presence of
sepsis, any clinical evidence of VOL (S3 gallop, bilateral basilar crackles, bilateral pedal
edema, jugular venous distension, pulmonary edema) and measurement of LV ejection
fraction (LVEF) within 48 hours of the BNP data were defined.
Comparison of BNP cut off of 20pg/ml vs Echocardiography as a screening tool in 
Cardiac Failure
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
Accuracy
All Unknown 
LVD
79%(69-86) 44%(35-54) 57%(48-65 69%(56-79 61%
Only Systolic 80%(50-98) 36%(30-44) 10%(6-16) 96%(87-99) 40%
Only Diastolic 75%(63-84) 38%(30-47) 40%(32-49) 73%(61-83) 51%
Systolic & 
Diastolic
100%(70-105) 35%(29-42) 8%(5-14) 100%(94-100) 39%
Subjects without 
Death or HF 
hospitalization
(Mean ± SD)
(N=598)
Subjects with 
Death or HF 
hospitalization
(Mean ± SD)
(N=87)
P–value
t-test
∆ ANP (pmol/ml) -21.5 ± 628.2 +293.7 ± 648.3 0.006
∆ NE (pg/ml) -48.5 ± 242.9 - 22.3 ± 232.5 0.04
∆ Brain natriuretic peptide (pmol/ml) - 5.3 ± 35.8 + 1.2 ± 52.0 0.15
∆ Endothelin (pg/ml) - 0.63 ± 3.63 - 0.36 ± 2.25 0.36
∆ Angiotensin (pg/ml) + 5.8 ± 30.2 + 13.5 ± 34.8 0.59
∆ Aldosterone (pg/ml) - 9.5 ± 102.2 - 14.7 ± 102.5 0.92
∆ Epinephrine (pg/ml) - 24.1 ± 92.4 - 26.7 ± 56.5 0.80
